Bindley Bioscience Center


The Bindley Bioscience Center (BBC) has been awarded 14 grants since the Center began in April 2002 for a total of $16,645,596 in sponsored program research. The BBC also is working with 16 "in-house" or pilot projects that provide preliminary research results that can lead to larger sponsored research projects. This number of projects continues to grow as faculty with interdisciplinary ideas seek to engage with the BBC. Pilot projects add specificity and credibility to large Center grant proposals requiring cores that include several projects.

All of these BBC projects inherently have engagement possibilities that may be cultivated both with Purdue faculty as well as external partners. Several new interdisciplinary projects have been enabled by the BBC's ability to provide expertise and the instrumentation. Furthermore, the BBC brings practical experience gained both within and outside of academia to move projects forward with an efficiency rarely seen in academic research projects.

Interested in engaging in a project with the Bindley Bioscience Center? Learn how to participate

Funded Projects

  1. APT, Analytical Proteomics Team

PI: Fred E Regnier
NCI 09/28/2006-08/31/2011

Biomarker identification and characterization holds great promise for more precise diagnoses and for tailored ?therapies. The heterogeneity of human cancers and unmet medical needs in these diseases provides a compelling argument to focus biomarker development in cancer. Mass spectrometry (MS)- based proteomics approaches have provided insight into biomarkers of cancer and other diseases with femtomole sensitivity and high analytical precision but the results have proven difficult to reproduce owing to the complexity of human biofluids and to the protocols employed in these approaches. This CPTAC proposal will develop robust protocols and standards for MS proteomics employing both electrospray ionization (ESI) and Matrix Assisted Laser Desorption Ionization (MALDI) platforms. Ion mobility MS provides several orders of magnitude increased dynamic range and protocols for detection of cancer biomarker candidates will be further explored with this emerging technology platform. The consortium will employ high specificity immunologic reagents to develop platforms for precise detection and quantification of biomarkers of relevance for breast and prostate cancer. Immunoaffinity selection of specific biomarker proteins will be achieved as a sample fractionation step using nano-scale immunoaffinity columns prior to MS detection and quantification of specific proteins. An emerging technology incorporating specific antibodies on a microfabricated 'bioCD' read by spinning disc inferometry enables label-free evaluation of hundreds of analytes from hundreds of samples in minutes. We will focus on candidate biomarkers relevant for breast and prostate cancer from the NFkB and STAT3 signaling pathways. Three for-profit and 1 not-for-profit corporate partner will join several academic groups with deep expertise and extensive resources in proteomics technologies to most efficiently evaluate and roll out robust protocols and standards for MS- and affinity proteomics approaches. Prostate cancer samples will be made available from the NCI-sponsored ECOG trial; breast cancer patient and control samples will be collected specifically for this consortium by the Hoosier Oncology Group from throughout the State and region. Standardized sample collection organized from the Indiana U. School of Medicine, will ensure a diverse cross section of patient demographic groups. Three additional corporate partners will provide key technologies and consultation to improve team efficacy.

About Bindley

Interdisciplinary life sciences and engineering researchers collaborate to explore new technologies and scientific knowledge that impact the broad boundaries of plant, animal, and human diseases.


Current Events

No current events were found.


Bindley Bioscience Center
1203 W. State Street
Purdue University
West Lafayette, IN 47907-2057